2 results
Approved WMOPending
Primary Objective• To assess the effect of ALX148 + pembrolizumab + 5FU + platinum on 12-month overall survival (OS) rate and objective response rate (ORR)in patients with metastatic or unresectable, recurrent HNSCC who have not yet been treated…
Approved WMORecruiting
The aim is to see whether intradialytic parenteral nutrition is an efective treatment against the loss of muscle mass